Drug Trial Radar · NCT07890376
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition. Participation in the study will last about 58 weeks.
Conditions
- Obesity
- Overweight
Interventions
LY4086940Drug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Baseline, Week 32
Locations
46 sites in 2 countries. Site status is shown where the registry gives one.
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona
Headlands Research - Scottsdale
Scottsdale, Arizona
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona
NorCal Medical Research, Inc
Greenbrae, California
Velocity Clinical Research, Huntington Park
Huntington Park, California
Peninsula Research Associates
Rolling Hills Estates, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Stamford Therapeutics Consortium
Stamford, Connecticut
New Horizon Research Center
Miami, Florida
Indago Research & Health Center, Inc
Miami Lakes, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Charter Research - Winter Park
Orlando, Florida
Charter Research - Lady Lake
The Villages, Florida
Medical Research Partners
Ammon, Idaho
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas
Knownwell
Needham, Massachusetts
Lucida Clinical Trials
New Bedford, Massachusetts
Headlands Research - Detroit
Southfield, Michigan
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan
StudyMetrix Research
City of Saint Peters, Missouri
Clinvest Headlands Llc
Springfield, Missouri
Las Vegas Medical Research
Las Vegas, Nevada
Dent Neurologic Institute
Amherst, New York
Rochester Clinical Research, LLC
Rochester, New York
Monroe Biomedical Research
Monroe, North Carolina
Lucas Research, Inc
Morehead City, North Carolina
Lucas Research, Inc.
New Bern, North Carolina
CTI Clinical Research Center
Cincinnati, Ohio
Tribe Clinical Research, LLC
Greenville, South Carolina
Quality Medical Research
Nashville, Tennessee
IMA Clinical Research Austin
Austin, Texas
Velocity Clinical Research, Dallas
Dallas, Texas
FutureSearch Trials of Dallas
Dallas, Texas
Endeavor Clinical Trials
San Antonio, Texas
Texas Valley Clinical Research
Weslaco, Texas
Sovah Clinical Research-River District
Danville, Virginia
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington
Cicemo Srl
Buenos Aires, Argentina
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.